Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Vaccines in 2017

Closing in on a Zika virus vaccine

Nature Reviews Immunology volume 18, pages 89–90 (2018)Cite this article

Subjects

Over the past 2 years, Zika virus (ZIKV) has emerged as a pathogen capable of causing devastating congenital malformations in the developing fetus and significant neurological disease in adults. In 2017, substantial progress has been made towards the development, immunological analysis and preclinical evaluation of vaccine platforms to prevent the pathologies associated with ZIKV infection.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Vaccine-based approaches to protect against congenital ZIKV syndrome.

References

  1. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 1129–1132 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474–478 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237–240 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114–1125. e10 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. George, J. et al. Prior exposure to Zika virus significantly enhances peak Dengue-2 viremia in rhesus macaques. Sci. Rep. 7, 10498 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Richner, J. M. et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170, 273–283. e12 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shan, C. et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat. Med. 23, 763–767 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shan, C. et al. A single-dose live-attenuated vaccine prevents Zika virus infection, pregnancy transmission, and testis damage. Nat. Commun. 8, 676 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Elong Ngono, A. et al. Mapping and role of the CD8+ T cell response during primary Zika virus infection in mice. Cell Host Microbe 21, 35–46 (2017).

    Article  CAS  PubMed  Google Scholar 

  11. Wen, J. et al. Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells. Nat. Microbiol. 2, 17036 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Michael S. Diamond is at the Departments of Medicine, Pathology and Immunology, and Molecular Microbiology, and The Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St Louis, Missouri 63110, USA,

    Michael S. Diamond

  2. Carolyn B. Coyne is at the Department of Pediatrics, and The Center for Microbial Pathogenesis, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15224, USA,

    Carolyn B. Coyne

Authors
  1. Michael S. Diamond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolyn B. Coyne
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.S.D and C.B.C. wrote the article. Both authors reviewed and edited the manuscript before submission.

Corresponding authors

Correspondence to Michael S. Diamond or Carolyn B. Coyne.

Ethics declarations

Competing interests

M.S.D. is a consultant for Aviana, Inbios, Sanofi-Pasteur and Takeda and is on the scientific advisory boards of Moderna and OvaGene.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diamond, M., Coyne, C. Closing in on a Zika virus vaccine. Nat Rev Immunol 18, 89–90 (2018). https://doi.org/10.1038/nri.2017.132

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nri.2017.132

This article is cited by

Search

Advanced search

Quick links

Nature Briefing Microbiology

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing: Microbiology